Enfusion, Inc. (NYSE:ENFN) CEO Sells $28,070.23 in Stock

Enfusion, Inc. (NYSE:ENFN - Get Free Report) CEO Oleg Movchan sold 2,771 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total value of $28,070.23. Following the sale, the chief executive officer now directly owns 526,702 shares of the company's stock, valued at approximately $5,335,491.26. This trade represents a 0.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Enfusion Stock Performance

ENFN stock traded down $0.32 on Friday, reaching $9.97. The company's stock had a trading volume of 351,791 shares, compared to its average volume of 403,182. The business has a fifty day simple moving average of $10.11 and a two-hundred day simple moving average of $9.19. Enfusion, Inc. has a 12-month low of $7.52 and a 12-month high of $11.38. The firm has a market cap of $1.28 billion, a PE ratio of 249.31, a PEG ratio of 3.98 and a beta of 0.95.

Institutional Trading of Enfusion

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENFN. Centiva Capital LP lifted its position in Enfusion by 5.0% during the third quarter. Centiva Capital LP now owns 25,596 shares of the company's stock valued at $243,000 after buying an additional 1,227 shares during the period. Harbor Capital Advisors Inc. lifted its position in Enfusion by 12.4% during the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company's stock valued at $113,000 after buying an additional 1,315 shares during the period. Azora Capital LP lifted its position in Enfusion by 6.8% during the third quarter. Azora Capital LP now owns 29,827 shares of the company's stock valued at $283,000 after buying an additional 1,890 shares during the period. 272 Capital LP increased its holdings in shares of Enfusion by 1.5% during the second quarter. 272 Capital LP now owns 139,180 shares of the company's stock valued at $1,186,000 after acquiring an additional 2,000 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Enfusion by 27.7% during the second quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company's stock valued at $167,000 after acquiring an additional 4,239 shares in the last quarter. Hedge funds and other institutional investors own 81.05% of the company's stock.

Analysts Set New Price Targets

ENFN has been the subject of a number of analyst reports. Stifel Nicolaus increased their price objective on Enfusion from $11.00 to $13.00 and gave the company a "buy" rating in a research note on Wednesday, December 18th. Piper Sandler increased their price objective on Enfusion from $10.00 to $11.50 and gave the company a "neutral" rating in a research note on Monday, December 23rd. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $10.25.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.